Compare RMBS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | RDY |
|---|---|---|
| Founded | 1990 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.6B |
| IPO Year | 1997 | 2001 |
| Metric | RMBS | RDY |
|---|---|---|
| Price | $146.35 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $137.00 | $16.90 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 27.88 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $707,630,000.00 | N/A |
| Revenue This Year | $16.01 | $7.72 |
| Revenue Next Year | $16.23 | $3.50 |
| P/E Ratio | $270.98 | ★ $18.67 |
| Revenue Growth | ★ 27.13 | N/A |
| 52 Week Low | $53.11 | $12.19 |
| 52 Week High | $161.80 | $16.17 |
| Indicator | RMBS | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 53.45 |
| Support Level | $90.31 | $12.90 |
| Resistance Level | $161.80 | $14.04 |
| Average True Range (ATR) | 9.32 | 0.24 |
| MACD | 1.36 | 0.03 |
| Stochastic Oscillator | 68.06 | 85.67 |
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.